We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
-9.24%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.31B
AUM Growth
-$337M
(-20%)
Cap. Flow
-$134M
Cap. Flow
% of AUM
-10.16%
Top 10 Holdings %
Top 10 Hldgs %
74.12%
Holding
34
New
–
Increased
13
Reduced
4
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vaxcyte
PCVX
|
+$13.2M |
| 2 |
CBLL
CeriBell Inc
CBLL
|
+$12.3M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$11.8M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$9.18M |
| 5 |
ArriVent BioPharma
AVBP
|
+$8.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TEM
Tempus AI
TEM
|
+$138M |
| 2 |
Brookfield
BN
|
+$26.5M |
| 3 |
CRGX
CARGO Therapeutics
CRGX
|
+$24M |
| 4 |
Alibaba
BABA
|
+$9.22M |
| 5 |
Salesforce
CRM
|
+$6.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.89% |
| 2 | Technology | 14.07% |
| 3 | Financials | 9.29% |
| 4 | Consumer Discretionary | 3.75% |
| 5 | Industrials | 0.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Morningstar Total Stock Market ETF
VTI
$646B
| $285M | 21.71% |
1,038,550
| – | – |
|
|
2
Brookfield
BN
$102B
| $122M | 9.29% |
3,496,245
-702,000
| -17% | -$26.5M |
|
|
3
Edgewise Therapeutics
EWTX
$4.28B
| $118M | 8.95% |
5,350,000
+350,000
| +7% | +$9.18M |
|
4
ASML
ASML
$596B
| $110M | 8.36% |
165,836
| – | – |
|
|
5
Salesforce
CRM
$154B
| $73.2M | 5.57% |
272,801
-21,100
| -7% | -$6.56M |
|
6
Mirum Pharmaceuticals
MIRM
$6.56B
| $67.6M | 5.14% |
1,500,000
| – | – |
|
7
Insmed
INSM
$22.4B
| $55.3M | 4.21% |
724,666
| – | – |
|
8
Recursion Pharmaceuticals
RXRX
$1.58B
| $51.1M | 3.89% |
9,665,128
-449,505
| -4% | -$3.28M |
|
|
9
Alibaba
BABA
$276B
| $49.2M | 3.75% |
372,327
-80,000
| -18% | -$9.22M |
|
|
10
Crinetics Pharmaceuticals
CRNX
$8.88B
| $42.8M | 3.25% |
1,275,000
+314,785
| +33% | +$11.8M |
|
11
BioMarin Pharmaceuticals
BMRN
$11.9B
| $34.6M | 2.63% |
490,000
| – | – |
|
|
12
ArriVent BioPharma
AVBP
$1.4B
| $34.6M | 2.63% |
1,872,142
+351,515
| +23% | +$8.6M |
|
|
13
Vaxcyte
PCVX
$7.65B
| $34.6M | 2.63% |
915,000
+165,000
| +22% | +$13.2M |
|
|
MRUS
14
DELISTED
Merus
MRUS
| $33.2M | 2.53% |
789,129
+39,129
| +5% | +$1.71M |
|
15
Viridian Therapeutics
VRDN
$2.2B
| $30.3M | 2.31% |
2,250,300
+300
| +0% | +$5.11K |
|
16
Pharvaris
PHVS
$2.28B
| $27.1M | 2.06% |
1,725,000
| – | – |
|
|
FOLD
17
DELISTED
Amicus Therapeutics
FOLD
| $22.4M | 1.71% |
2,750,000
+250,000
| +10% | +$2.31M |
|
18
Celldex Therapeutics
CLDX
$2.94B
| $21.8M | 1.66% |
1,200,000
+200,000
| +20% | +$4.47M |
|
|
BPMC
19
DELISTED
Blueprint Medicines
BPMC
| $20.3M | 1.54% |
228,804
+53,804
| +31% | +$5.25M |
|
|
ZBIO
20
Zenas BioPharma
ZBIO
$1.96B
| $17.5M | 1.33% |
2,214,967
+614,967
| +38% | +$4.81M |
|
|
CBLL
21
CeriBell Inc
CBLL
$673M
| $16.9M | 1.29% |
880,000
+551,191
| +168% | +$12.3M |
|
|
VERV
22
DELISTED
Verve Therapeutics
VERV
| $13.7M | 1.04% |
3,000,000
+600,000
| +25% | +$4.02M |
|
23
Rocket Pharmaceuticals
RCKT
$343M
| $7.34M | 0.56% |
1,100,000
| – | – |
|
24
4D Molecular Therapeutics
FDMT
$502M
| $6.3M | 0.48% |
1,950,000
+450,000
| +30% | +$2.12M |
|
25
Lexeo Therapeutics
LXEO
$338M
| $3.9M | 0.3% |
1,122,581
| – | – |
|
Similar funds
HCA
GX
MP
FLII
IC
CCA
WCM
IA
Novo Holdings A/S's Q1 2025 Portfolio in Review
As of Q1 2025, Novo Holdings A/S held 34 positions worth $1.31B, down 20% from $1.65B the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Novo Holdings A/S withdrew a net $134M in Q1 2025, closing 3 positions and reducing 4 holdings. Its most notable exit was Tempus AI, an estimated $138M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 55% a quarter earlier, followed by Technology and Financials.
Against the trend, Novo Holdings A/S added an estimated $13.2M to Vaxcyte.
- Novo Holdings A/S added most to Vaxcyte in Q1 2025, an estimated $13.2M increase.
- Novo Holdings A/S's biggest Q1 2025 reduction was Brookfield, cutting an estimated $26.5M.
- Novo Holdings A/S fully exited Tempus AI in Q1 2025, selling an estimated $138M.
- Novo Holdings A/S's ten largest holdings make up 74% of its $1.31B portfolio in Q1 2025.
- Novo Holdings A/S opened 0 new positions and closed 3 in Q1 2025.
- Novo Holdings A/S's portfolio value fell 20% quarter-over-quarter to $1.31B.
Based on Novo Holdings A/S's 13F filing for Q1 2025, filed 15 May 2025.